Literature DB >> 8062149

Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate.

M P Collinson, C J Tyrrel, C Hutton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8062149     DOI： 10.1007/bf00295959

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  20 in total

1.  A new way to induce oestrogen-deficiency osteopaenia in the rat: comparison of the effects of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition.

Authors:  A Goulding; E Gold
Journal:  J Endocrinol       Date:  1989-05       Impact factor: 4.286

2.  The syndrome of spinal osteoporosis.

Authors:  P D Saville
Journal:  Clin Endocrinol Metab       Date:  1973-07

Review 3.  Male hypogonadism.

Authors:  W D Odell; R S Swerdloff
Journal:  West J Med       Date:  1976-06

4.  Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male.

Authors:  D T Baran; M A Bergfeld; S L Teitelbaum; L V Avioli
Journal:  Calcif Tissue Res       Date:  1978-12-08

5.  [Hormone studies in human senile osteoporosis].

Authors:  G Guarneri; C Foresta; G Ruzza; A Meneghello; M P Sidran; F Cafiero
Journal:  Minerva Med       Date:  1981-09-08       Impact factor: 4.806

6.  Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation.

Authors:  R M Francis; M Peacock; J E Aaron; P L Selby; G A Taylor; J Thompson; D H Marshall; A Horsman
Journal:  Bone       Date:  1986       Impact factor: 4.398

7.  Reduced calcitonin reserve in young hypogonadic osteoporotic men.

Authors:  C Foresta; G Scanelli; G P Zanatta; B Busnardo; C Scandellari
Journal:  Horm Metab Res       Date:  1987-06       Impact factor: 2.936

8.  Testosterone and calcitonin plasma levels in hypogonadal osteoporotic young men.

Authors:  C Foresta; G P Zanatta; B Busnardo; G Scanelli; C Scandellari
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

9.  Osteoporosis in men with hyperprolactinemic hypogonadism.

Authors:  S L Greenspan; R M Neer; E C Ridgway; A Klibanski
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

10.  [Osteoporosis in Klinefelter's syndrome Quantitative bone histological data in 5 cases and relationship with hormonal deficiency (author's transl)].

Authors:  P Delmas; P J Meunier
Journal:  Nouv Presse Med       Date:  1981-02-28
View more
  5 in total

1.  Fracture risk in patients with prostate cancer on androgen deprivation therapy.

Authors:  Ana M López; María A Pena; Rafael Hernández; Fernando Val; Bernardo Martín; José A Riancho
Journal:  Osteoporos Int       Date:  2005-02-16       Impact factor: 4.507

2.  Surgical Decompression of High-Grade Spinal Cord Compression from Hormone Refractory Metastatic Prostate Cancer.

Authors:  Muhammad Omar Chohan; Sweena Kahn; Gustav Cederquist; Anne S Reiner; Joseph Schwab; Ilya Laufer; Mark Bilsky
Journal:  Neurosurgery       Date:  2018-05-01       Impact factor: 4.654

Review 3.  Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Sandra L Spoelstra; Rouhi Fazelzad; Martine T E Puts
Journal:  Support Care Cancer       Date:  2016-07-22       Impact factor: 3.603

4.  The use of zoledronic acid in Japanese men with stage D2 prostate cancer.

Authors:  Kogenta Nakamura; Yoshiaki Yamada; Charles J Rosser; Maki Arakawa; Kenji Zennmai; Yoshiharu Kato; Masahito Watanabe; Remi Katsuda; Motoi Tobiume; Katsuya Naruse; Shigeyuki Aoki; Tomohiro Taki; Hiroko Saito; Takaaki Hasegawa; Nobuaki Honda
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

Review 5.  Background to and management of treatment-related bone loss in prostate cancer.

Authors:  Alfredo Berruti; Marcello Tucci; Carlo Terrone; Gabriella Gorzegno; Roberto M Scarpa; Alberto Angeli; Luigi Dogliotti
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.